During the three months ended September 30, 2024, the Company sold, under the Open Market Sale Agreement with Jefferies LLC, ...

Non-small cell lung cancer (NSCLC) remains a predominant cause of cancer-related mortality worldwide. In recent years, immune checkpoint inhibitors (ICIs) have emerged as a transformative therapeutic ...

Glioblastoma (GBM) is the most common kind of malignant brain tumor in adults. In recent years, the tumor microenvironment ...

A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a ...

This was the basis to develop a comprehensive single-cell RNA-sequencing atlas of the MM- tumor-immune microenvironment in ...

In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...

For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study ...

Glioblastoma is the most common kind of malignant brain tumor in adults. So far, no treatment has been able to make this ...

Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

not all the cancer cells necessarily have the structure the T-cells can recognize and attack. And third, solid tumors in human tissue have a microenvironment that fends off immune system attacks.

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing CohortInterim Data from Atopic Dermatitis Trial ...

Researchers have developed an innovative CAR T-cell therapy to combat glioblastoma, the most common malignant brain tumor in ...